Anixa Biosciences Inc Dossier - Source-backed chat

Anixa Biosciences Inc

ANIXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.73

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.93Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $101.9M

Enterprise Value $100.4M

Shares Outstanding 34.3M diluted

Next Earnings Date12 Jan 2027

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Anixa Biosciences is a clinical-stage biotechnology company with a highly differentiated, dual-pillar oncology platform focused on cancer therapeutics (CAR-T) and cancer vaccines. The company's breast cancer vaccine, targeting alpha-lactalbumin, has successfully completed its Phase 1 trial, demonstrating a 74% protocol-defined immune response rate with favorable tolerability, and is now transitioning to Phase 2. Concurrently, its ovarian cancer CAR-T therapy (lira-cel) is showing encouraging survival observations in heavily pretreated patients, with regulatory clearance secured for substantial dose escalation. Backed by strong institutional partnerships (Cleveland Clinic, Moffitt Cancer Center, and the U.S. Department of Defense) and a debt-free balance sheet, Anixa represents a high-upside biotechnology play as it approaches key Phase 2 clinical inflection points.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$7.00

Mean target$10.00

High · most bullish analyst$14.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Phase 2 breast cancer vaccine trials face enrollment delays or fail to replicate Phase 1 immunogenicity. Lira-cel dose escalation is halted due to safety concerns or off-target toxicities. Continued cash burn in the absence of licensing revenues forces highly dilutive equity financing, depressing the share price.

Base CaseCentral scenario

The breast cancer vaccine successfully initiates Phase 2 trials with Cytovance Biologics delivering cGMP clinical materials. Lira-cel continues to show positive survival data in the ongoing Phase 1 dose-escalation cohorts. The company maintains its debt-free status and manages cash burn through strategic ATM equity raises, keeping dilution within reasonable limits.

Bull CaseUpside scenario

Anixa's diversified oncology pipeline, featuring a breast cancer vaccine, an ovarian cancer vaccine, and a novel CAR-T therapy, reduces single-asset development risk. Strong partnerships with world-renowned institutions like Cleveland Clinic and Moffitt Cancer Center provide scientific validation, while a robust net cash position of $13.7M ensures a runway through Q1 2028. Positive Phase 1 data for the breast cancer vaccine and early survival signals in the CAR-T trial offer significant clinical catalysts.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated dual-pillar oncology pipeline targeting both cancer prevention (vaccines) and treatment (CAR-T).
Strong clinical validation with a 74% immune response rate in the Phase 1 breast cancer vaccine trial.
Strategic collaborations with world-class institutions including Cleveland Clinic, Moffitt Cancer Center, and the U.S. Department of Defense.
Debt-free balance sheet with no preferred stock or warrants, providing a clean capital structure.

Key Investment Risks

Early-stage clinical risk with primary assets still in Phase 1/2 development.
Pre-revenue status with ongoing net losses ($2.52 million in Q2 2026) and reliance on equity financing (ATM offerings) for funding.
Potential shareholder dilution from future capital raises to fund expensive late-stage clinical trials.

Thesis Invalidation Triggers

Failure to initiate or enroll patients in the planned Phase 2 breast cancer vaccine trial.
Severe adverse safety events or lack of efficacy signals in the lira-cel CAR-T dose-escalation cohorts.
Inability to secure additional funding or strategic partnerships, leading to a severe cash runway shortage.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.